Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor H binding protein

Infection and Immunity

Volumn 80, Issue 1, 2012, Pages 187-194

  Giuntini, Serena ^a   Reason, Donald C ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FHBP MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; FACTOR H BINDING PROTEIN, NEISSERIA MENINGITIDIS; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS;

ANTIBODY PRODUCTION; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; PRIORITY JOURNAL; WILD TYPE; ADULT; ANIMAL; COMPLEMENT ACTIVATION; DRUG EFFECT; HUMAN; IMMUNOLOGY; MICROBIAL VIABILITY; MOUSE; NEISSERIA MENINGITIDIS; SERUM BACTERICIDAL ACTIVITY;

ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; EPITOPES; HUMANS; IMMUNOGLOBULIN G; MICE; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS;

EID: 84857083353     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05956-11     Document Type: Article

References (39)

1. Agarwal S, et al. 2010. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae. J. Immunol. 185:507-516.
2. Agarwal S, et al. 2011. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. mBio 2:e00178-e00111.
3. Beernink PT, Lopasso C, Angiolillo A, Felici F, Granoff D. 2009. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol. Immunol. 46:1647-1653.
4. Beernink PT, et al. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 186:3606 -3614.
5. Beernink PT, et al. 2008. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate, factor H-binding protein. Infect. Immun. 76:4232-4240.
6. Blasius R, Strittmatter W, Crowe B, Achtman M. 1990. Two distinct outer membrane serotype subcomplexes of Neisseria meningitidis serogroup A. Infect. Immun. 58:2008 -2010.
7. Bruggemann M, et al. 1987. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J. Exp. Med. 166:1351-1361.
8. Burton DR, Gregory L, Jefferis R. 1986. Aspects of the molecular structure of IgG subclasses. Monogr. Allergy 19:7-35.
9. Callaghan MJ, et al. 2011. Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci. Infect. Immun. 79:2810 -2818.
10. Donnelly J, et al. 2010. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of proteinbased vaccines. Proc. Natl. Acad. Sci. U. S. A. 107:19490 -19495.
11. Finne J, Leinonen M, Makela PH. 1983. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet ii:355-357.
12. Garred P, Michaelsen TE, Aase A. 1989. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand. J. Immunol. 30:379 -382.
13. Giuliani MM, et al. 2005. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect. Immun. 73:1151-1160.
14. Giuntini S, Reason DC, Granoff DM. 2011. Complement-mediated bactericidal activity of anti-factorHbinding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect. Immun. 79:3751-3759.
15. Granoff DM. 2010. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50(Suppl. 2):S54 -S65.
16. Granoff DM, et al. 1998. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J. Immunol. 160:5028 -5036.
17. Granoff DM, Welsch JA, Ram S. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77:764 -769.
18. Hou VC, Koeberling O, Welsch JA, Granoff DM. 2005. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J. Infect. Dis. 192:580 -590.
19. Hourcade DE, Wagner LM, Oglesby TJ. 1995. Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis. J. Biol. Chem. 270:19716 -19722.
20. Jennings HJ, Lugowski C. 1981. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127:1011-1018.
21. Koeberling O, Welsch JA, Granoff DM. 2007. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. Vaccine 25:1912-1920.
22. Madico G, et al. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510.
23. Marzoa J, et al. 2009. Analysis of outer membrane porin complexes of Neisseria meningitidis in wild-type and specific knockout mutant strains. Proteomics 9:648-656.
24. Marzoa J, Sanchez S, Ferreiros CM, Criado MT. 2010. Identification of Neisseria meningitidis outer membrane vesicle complexes using 2-D high resolution clear native/SDS-PAGE. J. Proteome Res. 9:611- 619.
25. Masignani V, et al. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789 -799.
26. Michaelsen TE, Frangione B, Franklin EC. 1977. Primary structure of the "hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit. J. Biol. Chem. 252:883- 889.
27. Michaelsen TE, Garred P, Aase A. 1991. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur. J. Immunol. 21:11-16.
28. Michaelsen TE, et al. 2003. Binding properties and antibacterial activities of V-region identical, human IgG and IgM antibodies, against group B Neisseria meningitidis. Biochem. Soc. Trans. 31:1032-1035.
29. Michaelsen TE, Sandlie I, Bratlie DB, Sandin RH, Ihle O. 2009. Structural difference in the complement activation site of human IgG1 and IgG3. Scand. J. Immunol. 70:553-564.
30. Murphy E, et al. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200:379 -389.
31. Pagotto FJ, Salimnia H, Totten PA, Dillon JR. 2000. Stable shuttle vectors for Neisseria gonorrhoeae, Haemophilus spp. and other bacteria based on a single origin of replication. Gene 244:13-19.
32. Pajon R, Beernink PT, Harrison LH, Granoff DM. 2010. Frequency of factor H-binding protein modular groups and susceptibility to crossreactive bactericidal activity in invasive meningococcal isolates. Vaccine 28:2122-2129.
33. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM. 2011. Meningococcal factorHbinding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl. Trop. Dis. 5:e1302. doi:10.1371/journal.pntd.0001302.
34. Sadarangani M, Pollard AJ. 2010. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect. Dis. 10:112-124.
35. Scarselli M, et al. 2009. Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. J. Mol. Biol. 386:97-108.
36. Song J, Minetti CA, Blake MS, Colombini M. 1999. Meningococcal PorA/C1, a channel that combines high conductance and high selectivity. Biophys. J. 76:804-813.
37. Vidarsson G, et al. 2001. Activity of human IgG and IgA subclasses in immune defense against Neisseria meningitidis serogroup B. J. Immunol. 166:6250-6256.
38. Welsch JA, Ram S, Koeberling O, Granoff DM. 2008. Complementdependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197:1053-1061.
39. Welsch JA, Rossi R, Comanducci M, Granoff DM. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol. 172:5606-5615.